Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 4/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | FASN | P49327 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TERT | O14746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3131194 | 0.81 | KMT2A (0.73) | KMT2AALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL29581156 | 0.81 | KMT2A (1.00) | KMT2AALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL214075 | 0.81 | KMT2A (1.00) | KMT2AALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL8304311 | 0.79 | KMT2A (0.81) | KMT2AALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL16719938 | 0.79 | KMT2A (0.64) | KMT2AALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL16719747 | 0.79 | KMT2A (0.64) | KMT2AALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL11687991 | 0.78 | KMT2A (0.92) | KMT2AALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL10103705 | 0.76 | KMT2A (0.76) | KMT2AALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL11663415 | 0.73 | KMT2A (0.71) | KMT2AALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL11685259 | 0.73 | KMT2A (0.70) | KMT2AALDH1A1KDM4EMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1861365-A1 | N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS | Nycomed GmbH (DE) | 2007-12-05 | — | — | EP | claimed |
| WO-2006097474-A1 | N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS | NYCOMED GMBH (DE) | 2006-09-21 | — | — | WO | claimed |
| US-20230201161-A1 | Combination comprising HDAC inhibitor, LAG-3 inhibitor and a PD-1 inhibitor or PD-L1 inhibitor for cancer treatment | 4SC AG (DE) | 2023-06-29 | — | — | US | disclosed |
| US-20210145799-A1 | PHARMACEUTICAL COMBINATION PRODUCTS COMPRISING A HISTONE DEACETYLASE (HDAC) INHIBITOR AND A TLR7 AGONIST AND/OR TLR8 AGONIST FOR THE TREATMENT OF CANCER | 4SC AG (DE) | 2021-05-20 | — | — | US | disclosed |
| US-20210113528-A1 | Combination comprising HDAC inhibitor and CD137 agonist for cancer therapy | 4SC AG (DE) | 2021-04-22 | — | — | US | disclosed |
| WO-2021064188-A1 | COMBINATION COMPRISING HDAC INHIBITOR, CTLA-4 INHIBITOR AND A PD-1 INHIBITOR OR PD-L1 INHIBITOR FOR CANCER TREATMENT | 4SC AG (DE) | 2021-04-08 | — | — | WO | disclosed |
| EP-3781557-A1 | PHARMACEUTICAL COMBINATION PRODUCTS COMPRISING A HISTONE DEACETYLASE (HDAC) INHIBITOR AND A TLR7 AGONIST AND/OR TLR8 AGONIST FOR THE TREATMENT OF CANCER | 4SC AG (DE) | 2021-02-24 | — | — | EP | disclosed |
| EP-3781159-A1 | COMBINATION COMPRISING HDAC INHIBITOR, LAG-3 INHIBITOR AND A PD-1 INHIBITOR OR PD-L1 INHIBITOR FOR CANCER TREATMENT | 4SC AG (DE) | 2021-02-24 | — | — | EP | disclosed |
| EP-3773554-A1 | COMBINATION COMPRISING HDAC INHIBITOR AND CD137 AGONIST FOR CANCER THERAPY | 4SC AG (DE) | 2021-02-17 | — | — | EP | disclosed |
| CN-112105611-A | Pharmaceutical combination comprising a Histone Deacetylase (HDAC) inhibitor and a TLR7 agonist and/or a TLR8 agonist for the treatment of cancer | 4SC股份公司 | 2020-12-18 | — | — | CN | disclosed |
| CN-112055589-A | Combination comprising an HDAC inhibitor, a LAG-3 inhibitor and a PD-1 inhibitor or a PD-L1 inhibitor for the treatment of cancer | 4SC股份公司 | 2020-12-08 | — | — | CN | disclosed |
| US-4127501-A | BENZOXAZOLE, BENZOTHIAZOLE, BENZIMIDAZOLE, BENZOTRIAZOLE OR INDOLE DERIVATIVES | EASTMAN KODAK COMPANY (US) | 1978-11-28 | — | — | US | disclosed |
| US-4115348-A | DEGRADATION INHIBITORS | EASTMAN KODAK COMPANY (US) | 1978-09-19 | — | — | US | disclosed |
| US-4096115-A | Ultraviolet light stabilized polymers | EASTMAN KODAK COMPANY (US) | 1978-06-20 | — | — | US | disclosed |
| US-4075220-A | FOR POLYMERS | EASTMAN KODAK COMPANY (US) | 1978-02-21 | — | — | US | disclosed |
| US-4065427-A | Polychromophoric heterocyclic ultraviolet stabilizers and their use in organic compositions | EASTMAN KODAK COMPANY (US) | 1977-12-27 | — | — | US | disclosed |
| US-4017508-A | POLYMERS | EASTMAN KODAK COMPANY (US) | 1977-04-12 | — | — | US | disclosed |
| US-4000148-A | POLYMERS | EASTMAN KODAK COMPANY (US) | 1976-12-28 | — | — | US | disclosed |
| US-3981822-A | HETEROCYCLIC COMPOUNDS | EASTMAN KODAK COMPANY (US) | 1976-09-21 | — | — | US | disclosed |
| US-3957813-A | BENZOXAZOLYL PHENYL AROMATIC ESTER COMPOUNDS AND THEIR USE AS ULTRAVIOLET STABILIZERS IN ORGANIC COMPOSITIONS | EASTMAN KODAK COMPANY (US) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210145799-A1 | PHARMACEUTICAL COMBINATION PRODUCTS COMPRISING A HISTONE DEACETYLASE (HDAC) INHIBITOR AND A TLR7 AGONIST AND/OR TLR8 AGONIST FOR THE TREATMENT OF CANCER | HDAC8, TLR8, TLR7 | KMT2A 61/4885ALDH1A1 1191/4885KDM4E 319/4885 |
| US-20210113528-A1 | Combination comprising HDAC inhibitor and CD137 agonist for cancer therapy | HDAC7, HDAC1, HDAC11 | KMT2A 659/4885ALDH1A1 384/4885KDM4E 786/4885 |
| US-20230201161-A1 | Combination comprising HDAC inhibitor, LAG-3 inhibitor and a PD-1 inhibitor or PD-L1 inhibitor for cancer treatment | HDAC1, HDAC3, HDAC11 | KMT2A 185/4885ALDH1A1 315/4885KDM4E 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.